- Home
- RDHL vs GNPX Comparison
RDHL vs GNPX Comparison
Compare RDHL & GNPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDHL
- GNPX
- Stock Information
- Founded
- RDHL 2009
- GNPX 2009
- Country
- RDHL Israel
- GNPX United States
- Employees
- RDHL N/A
- GNPX N/A
- Industry
- RDHL Biotechnology: Pharmaceutical Preparations
- GNPX Biotechnology: Pharmaceutical Preparations
- Sector
- RDHL Health Care
- GNPX Health Care
- Exchange
- RDHL Nasdaq
- GNPX Nasdaq
- Market Cap
- RDHL 7.5M
- GNPX 7.1M
- IPO Year
- RDHL N/A
- GNPX 2018
- Fundamental
- Price
- RDHL $5.64
- GNPX $0.72
- Analyst Decision
- RDHL
- GNPX Strong Buy
- Analyst Count
- RDHL 0
- GNPX 1
- Target Price
- RDHL N/A
- GNPX $10.00
- AVG Volume (30 Days)
- RDHL 13.8K
- GNPX 450.5K
- Earning Date
- RDHL 08-29-2024
- GNPX 11-13-2024
- Dividend Yield
- RDHL N/A
- GNPX N/A
- EPS Growth
- RDHL N/A
- GNPX N/A
- EPS
- RDHL N/A
- GNPX N/A
- Revenue
- RDHL $3,707,000.00
- GNPX N/A
- Revenue This Year
- RDHL $224.90
- GNPX N/A
- Revenue Next Year
- RDHL $82.69
- GNPX N/A
- P/E Ratio
- RDHL N/A
- GNPX N/A
- Revenue Growth
- RDHL N/A
- GNPX N/A
- 52 Week Low
- RDHL $5.41
- GNPX $0.28
- 52 Week High
- RDHL $31.50
- GNPX $13.00
- Technical
- Relative Strength Index (RSI)
- RDHL 35.38
- GNPX 36.49
- Support Level
- RDHL $5.41
- GNPX $0.68
- Resistance Level
- RDHL $5.79
- GNPX $0.93
- Average True Range (ATR)
- RDHL 0.31
- GNPX 0.06
- MACD
- RDHL -0.05
- GNPX -0.00
- Stochastic Oscillator
- RDHL 14.26
- GNPX 15.66
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is focused primarily on the advancement of its development pipeline of clinical-stage therapeutic candidates. The company also commercializes in the U.S. GI-related products, Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). The company's current pipeline consists of five therapeutic candidates, which are Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, most of which are in clinical development.
About GNPX Genprex Inc.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.